Myoadenylate Deaminase Deficiency (MADD)

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 21 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Medical guide Rx Autoimmune, Genetic and Rare Diseases (A - Z) Feb 8, 2026 35 reads
Related reading

Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Myoadenylate deaminase deficiency is a muscle energy problem. In healthy muscle, an enzyme called myoadenylate deaminase (also named AMP deaminase 1, made by the AMPD1 gene) helps recycle energy during hard or repeated exercise. When this enzyme is missing or very low, the muscle cannot...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Myoadenylate deaminase deficiency is a muscle energy problem. In healthy muscle, an enzyme called myoadenylate deaminase (also named AMP deaminase 1, made by the AMPD1 gene) helps recycle energy during hard or repeated exercise. When this enzyme is missing or very low, the muscle cannot handle sudden energy demand in the usual way. Some people feel muscle pain, cramps, early fatigue, or weakness after exercise....

Key Takeaways

  • This article explains Types in simple medical language.
  • This article explains Causes in simple medical language.
  • This article explains Symptoms in simple medical language.
  • This article explains Diagnostic tests in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Myoadenylate deaminase deficiency is a muscle energy problem. In healthy muscle, an enzyme called myoadenylate deaminase (also named AMP deaminase 1, made by the AMPD1 gene) helps recycle energy during hard or repeated exercise. When this enzyme is missing or very low, the muscle cannot handle sudden energy demand in the usual way. Some people feel muscle pain, cramps, early fatigue, or weakness after exercise. Many people, however, have few or no symptoms. The condition is most often inherited in an autosomal recessive way, meaning both gene copies carry a change. It can also be seen secondarily with other muscle conditions. Rare Diseases InfoPubMed  This condition is not the same as multiple acyl-CoA dehydrogenase deficiency, which is also shortened as “MADD.” Here we are discussing myoadenylate deaminase deficiency of skeletal muscle (AMPD1).

Myoadenylate deaminase deficiency is a genetic muscle energy disorder. In healthy muscle, an enzyme called AMP deaminase 1 (AMPD1) helps recycle “used” energy molecules during exercise. When this enzyme is missing or weak, muscles have trouble keeping up with energy demand. Many people have no symptoms at all. Those who do may feel early tiredness, muscle pain, cramps, or weakness during or after exertion. The condition is usually inherited in an autosomal recessive way (you inherit two non-working copies of the AMPD1 gene). The disorder is fairly common in people of European ancestry and can range from silent to causing exercise intolerance or, rarely, episodes of severe muscle breakdown (rhabdomyolysis). There is no cure, but symptoms can often be reduced with smart pacing, training, fueling, and supportive care. MedlinePlusOrphaRare Diseases Info

Other names

Myoadenylate deaminase deficiency is also known as AMPD1 deficiency, adenosine monophosphate deaminase deficiency, muscle AMP deaminase deficiency, muscle myoadenylate deaminase deficiency, and MMDD. The enzyme involved is the muscle isoform AMP deaminase 1; the most common genetic variant reported in many populations introduces an early stop in the protein (often called Q12X or c.34C>T). Older articles may use “MADA deficiency.” NCBIScienceDirect

Types

1) Primary (inherited) AMPD1 deficiency.
This is due to pathogenic changes in AMPD1. People with two defective copies can have little or no enzyme in muscle. Symptoms range from none at all to exercise-induced myalgia, cramps, and early fatigue. Muscle biopsy may show absent enzyme staining. Genetic testing can confirm the diagnosis. Rare Diseases InfoPubMedNCBI

2) Secondary (acquired) reduction of AMPD activity.
Some muscle biopsies from people with other muscle diseases show reduced AMPD staining. Newer studies suggest this secondary deficiency is not a major driver of symptoms in inflammatory myopathies, but it can still appear as a finding. PubMedPMC

3) Coincidental or modifier state.
A common AMPD1 stop variant (such as Q12X) is frequent in some populations. Many carriers or even some biallelic individuals feel well, and AMPD1 deficiency can act as a modifier of other myopathies rather than the sole cause of symptoms. PMCResearchGate

During intense exercise, muscle uses high-energy molecules quickly. The purine nucleotide cycle helps keep energy flowing. Myoadenylate deaminase converts AMP to IMP, releasing ammonia and supporting pathways that feed the energy systems. Without this step, the muscle’s rapid energy balance is altered, which can lead to early fatigue, cramps, and post-exertional pain in some people. In classic forearm exercise testing, people with AMPD1 deficiency often show an impaired rise of ammonia after exercise while lactate may rise normally. PubMed+1rheumaknowledgy.com

Causes

Think of these as reasons why the enzyme is low or why symptoms appear.

  1. Biallelic AMPD1 gene variants (autosomal recessive). The main cause; both copies of the gene carry changes that reduce enzyme activity. Rare Diseases Info

  2. Common nonsense variant (Q12X; c.34C>T). A frequent stop-gain change linked to low enzyme in muscle. NCBIScienceDirect

  3. Compound heterozygosity. Two different AMPD1 variants on each gene copy can reduce enzyme function. NCBI

  4. Promoter or splicing variants in AMPD1. Less common changes that still lower enzyme level or function. NCBI

  5. Secondary reduction in inflammatory myopathies. AMPD staining can be reduced, though it likely does not drive symptoms. PubMed

  6. Secondary reduction in other myopathies (e.g., dystrophinopathies, mitochondrial myopathies) reported historically in biopsy series. PubMed

  7. Muscle disuse or deconditioning. Inactivity may be associated with lower enzyme staining in some biopsies. PubMed

  8. Aging muscle. Age-related muscle change can affect many enzymes, sometimes including AMPD on biopsy. PubMed

  9. Coexisting metabolic myopathy. Another energy-pathway disease can unmask or magnify symptoms from low AMPD activity. Mattioli 1885

  10. Endocrine stress (e.g., thyroid gland makes too little hormone. সহজ বাংলা: থাইরয়েড হরমোন কম।" data-rx-term="hypothyroidism" data-rx-definition="Hypothyroidism means the thyroid gland makes too little hormone. সহজ বাংলা: থাইরয়েড হরমোন কম।">hypothyroidism). Systemic metabolic slow-down may worsen exercise intolerance when AMPD is low (reported in broader myopathy workups). Mattioli 1885

  11. Acute illness (viral fever). Illness can trigger post-exertional myalgia in people with borderline enzyme reserve. Mattioli 1885

  12. Dehydration and heat. These raise muscle stress and cramps in those with energy pathway vulnerabilities. Mattioli 1885

  13. Electrolyte imbalance (low magnesium or potassium). Can intensify cramping when energy cycling is inefficient. Mattioli 1885

  14. Statins or myotoxic drugs. Medicines that stress muscle may expose underlying intolerance. Mattioli 1885

  15. Overtraining without conditioning. Sudden, intense effort can exceed energy support pathways. Mattioli 1885

  16. Nutritional insufficiency (poor intake or recovery nutrition) that limits energy substrates. Mattioli 1885

  17. Anemia. Lower oxygen delivery makes energy production harder and symptoms more likely. Mattioli 1885

  18. Connective tissue pain disorders. Coexisting pain can heighten perception of post-exercise myalgia. Mattioli 1885

  19. Genetic modifiers in other energy genes. Variants in other pathways may change symptom severity. Mattioli 1885

  20. Unknown or multifactorial. Many people with AMPD1 deficiency have few symptoms; when symptoms occur, multiple small factors often add up. PMC

Symptoms

  1. Exercise-induced muscle pain (myalgia). A dull or sharp ache after activity; often the main complaint. Rare Diseases Info

  2. Early fatigue. Getting tired faster than peers during repeated or intense effort. Rare Diseases Info

  3. Muscle cramps. Painful tightening during or after exertion. Rare Diseases Info

  4. Post-exertional weakness. Temporary “muscles feel heavy” sensation after an activity bout. PubMed

  5. Poor sprint or interval performance. Trouble with repeated high-effort bursts. PubMed

  6. Prolonged recovery time. Soreness or fatigue lasts longer than expected. PubMed

  7. Occasional swelling or pain when an area is touched or pressed. সহজ বাংলা: চাপ দিলে ব্যথা।" data-rx-term="tenderness" data-rx-definition="Tenderness means pain when an area is touched or pressed. সহজ বাংলা: চাপ দিলে ব্যথা।">tenderness of a muscle after overuse. Local infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation after heavy effort. PubMed

  8. Exercise-induced pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache or malaise. Systemic tired feeling after activity. Rare Diseases Info

  9. Reduced activity level by choice. People self-limit to avoid pain or fatigue. Rare Diseases Info

  10. Perceived weakness without true loss of power at rest. Often exam power is normal between episodes. PubMed

  11. Occasional elevated CK after heavy exertion. Lab sign of muscle stress in some cases. PubMed

  12. No symptoms at all (very common). Many individuals with enzyme deficiency feel fine. Rare Diseases Info

  13. Leg or thigh pain with hills or stairs. Short anaerobic efforts can be uncomfortable. PubMed

  14. Night cramps after daytime exertion. Delayed painful cramps in calves or thighs. Rare Diseases Info

  15. Reduced ability for back-to-back exercise sets. Repeats are harder than a single long steady effort. PubMed

Diagnostic tests

A) Physical examination (bedside assessment)

1) General neuromuscular exam.
Doctors check bulk, tone, strength, reflexes, and gait. In AMPD1 deficiency, the exam is often normal at rest because the problem shows mainly with exertion. This helps separate it from progressive weakness disorders. PubMed

2) Functional exercise observation.
Your clinician may watch you do repetitive heel-raises, step-ups, or chair stands. Early fatigue or cramping during repeats suggests an exercise-intolerance pattern rather than fixed weakness. PubMed

3) Pain mapping and palpation.
Gentle pressure identifies tender areas after activity. Localized tenderness after exertion supports a post-exercise myalgia pattern. PubMed

4) Range-of-motion and flexibility.
Shortened or tight muscle groups may worsen cramping. Finding tight calves or hamstrings guides stretching-based care, even though it does not confirm the enzyme defect. Mattioli 1885

5) Vital signs and systemic screen.
Pulse, blood pressure, hydration clues, and thyroid or anemia screens (by history) help rule out non-muscle causes of fatigue that can mimic or worsen symptoms. Mattioli 1885

B) Manual tests (simple, clinic-based performance tests)

6) Timed repeated sit-to-stand.
Measures how quickly the legs fatigue across sets. People with exertional intolerance may slow down on later sets even if baseline strength is normal. Mattioli 1885

7) Step-test or stair-climb repeats.
Short, repeated climbs can trigger the typical after-effort pain or cramps, reproducing the complaint safely under observation. PubMed

8) Handgrip repetition test.
Several quick grip squeezes track drop-off with repetition. A rapid decline mirrors poor burst energy recycling. PubMed

9) Six-minute walk with symptom rating.
This submaximal test records stamina and post-test soreness, helping to document functional impact over time. Mattioli 1885

10) Gentle resisted testing after exertion.
Strength checked immediately after a brief exertion may feel reduced due to pain or cramp, then recover at rest—another pattern consistent with exertional myalgia disorders. PubMed

C) Laboratory and pathological tests

11) Serum CK (creatine kinase).
CK can be normal at baseline and rise after very heavy exertion in some people. A normal CK does not rule out AMPD1 deficiency. PubMed

12) Ischemic forearm exercise test (IFET): lactate and ammonia.
This classic screening test measures lactate and ammonia after repeated handgrip under a blood-pressure cuff. In AMPD1 deficiency, ammonia rise is blunted or absent; lactate rises normally. This pattern helps distinguish it from other metabolic myopathies (e.g., McArdle disease shows the opposite pattern). PubMedrheumaknowledgy.comSAGE Journals

13) Purine metabolites after exercise (inosine, hypoxanthine).
In some studies, people with AMPD1 deficiency show lower increases of purine breakdown products after ischemic exercise, supporting the diagnosis. Portland Press

14) Muscle biopsy with enzyme histochemistry.
A small muscle sample can be stained for myoadenylate deaminase. Classic primary cases show absent staining with otherwise normal muscle structure. Enzyme assay can measure activity directly. PubMed+1PLOS

15) Molecular genetic testing of AMPD1.
DNA testing can confirm pathogenic variants (such as c.34C>T, p.Q12X) and is now a common, less invasive way to make the diagnosis. NCBI+1

16) Basic metabolic panel and thyroid tests.
These do not diagnose AMPD1 deficiency, but they exclude contributors (electrolyte issues, hypothyroidism) that can worsen muscle symptoms. Mattioli 1885

17) Complete blood count (CBC).
Screens for anemia, which can amplify fatigue and exercise intolerance. Again, this helps context, not the core enzyme defect. Mattioli 1885

D) Electrodiagnostic tests

18) Electromyography (EMG).
EMG is often normal or shows mild, nonspecific myopathic changes in AMPD1 deficiency. It mainly helps rule out nerve problems or other myopathies. PubMed

19) Nerve conduction studies (NCS).
Usually normal, because the issue is not in the nerve. Used to exclude neuropathies that may cause fatigue or cramps. PubMed

E) Imaging tests

20) Muscle MRI (or ultrasound) when needed.
Imaging is often normal between episodes, but can show edema during acute overuse or help exclude other structural myopathies. It is supportive, not diagnostic, for AMPD1 deficiency. PubMed

Non-pharmacological treatments

Physiotherapy & exercise

  1. Pacing and energy budgeting.
    Purpose: Prevent “boom-and-bust” cycles and reduce flares.
    Mechanism: Breaks activity into smaller bouts with rests so ATP demand stays within your muscle’s capacity.
    Benefits: More consistent days, fewer crashes, better confidence.

  2. Graded aerobic conditioning (low-moderate intensity).
    Purpose: Build a bigger aerobic base safely.
    Mechanism: Improves mitochondrial efficiency and capillary delivery so you rely less on emergency ATP recycling pathways.
    Benefits: Later onset of fatigue, better daily stamina.

  3. Interval training with generous recovery.
    Purpose: Tolerate short bursts without tipping into pain.
    Mechanism: Work-rest cycles prevent sustained ATP depletion; recovery clears metabolites.
    Benefits: Keeps function for stairs, chores, and short sprints.

  4. Warm-up (10–15 minutes) + cool-down.
    Purpose: Prepare muscle, reduce cramp risk.
    Mechanism: Increases temperature and blood flow, improving enzyme kinetics and flexibility.
    Benefits: Smoother starts, fewer early cramps.

  5. Hydration strategy with electrolytes.
    Purpose: Limit cramps and heat strain.
    Mechanism: Maintains fluid/electrolyte balance critical for muscle contraction and nerve signaling.
    Benefits: Less cramping, steadier effort in heat.

  6. Technique and movement efficiency coaching.
    Purpose: Reduce wasted energy.
    Mechanism: Optimizes biomechanics, shortens lever arms, and improves cadence.
    Benefits: Same task feels easier; fewer aches.

  7. Strength training (low-to-moderate load, higher reps).
    Purpose: Increase muscular endurance safely.
    Mechanism: Promotes oxidative fibers and local circulation without extreme ATP drain.
    Benefits: Better posture, lifting, and daily tasks.

  8. Eccentric load caution + concentric emphasis.
    Purpose: Lower delayed soreness risk.
    Mechanism: Eccentric contractions create more micro-damage; bias toward concentric/controlled tempos.
    Benefits: Able to train more consistently.

  9. Flexibility and gentle mobility (daily).
    Purpose: Reduce stiffness and guarding.
    Mechanism: Improves muscle length and neural glide; lowers pain amplification.
    Benefits: Easier starts after sitting; smoother gait.

  10. Heat therapy before activity; ice after overuse.
    Purpose: Prepare tissue and calm flares.
    Mechanism: Heat increases perfusion; ice dampens inflammation and nociception.
    Benefits: Fewer cramps going in, less soreness after.

  11. Soft-tissue work/massage or foam rolling.
    Purpose: Ease trigger bands and tenderness.
    Mechanism: Mechanical/neuromodulatory effects reduce tone and improve circulation.
    Benefits: Short-term pain relief, better range.

  12. Transcutaneous electrical nerve stimulation (TENS).
    Purpose: Non-drug pain control.
    Mechanism: Gate-control and descending inhibition reduce pain signaling.
    Benefits: Lets you move more during rehab.

  13. Activity-specific fueling plan (see diet section).
    Purpose: Avoid under-fueling.
    Mechanism: Pre-exercise carbohydrate supplies glycolytic substrate so ATP backup pathways are less stressed.
    Benefits: Less early fatigue, better sessions.

  14. Scheduled recovery days + sleep hygiene.
    Purpose: Allow repair and adaptation.
    Mechanism: Sleep consolidates neuromuscular learning and replenishes glycogen.
    Benefits: Fewer setbacks; performance gradually rises.

  15. Flare plan.
    Purpose: Respond early to prevent escalation.
    Mechanism: Temporary activity reduction, fluids/electrolytes, gentle mobility, topical analgesia.
    Benefits: Faster resolution, less fear of activity.

Mind–body & “educational therapy” (and a note on gene therapy)

  1. Pain neuroscience education (PNE).
    Purpose: Reduce fear-avoidance.
    Mechanism: Understanding how pain is modulated lowers threat signals and helps graded exposure.
    Benefits: Better adherence, less catastrophizing.

  2. Cognitive behavioral therapy (CBT) for pacing and coping.
    Purpose: Build sustainable routines and confidence.
    Mechanism: Skills for goal-setting, activity scheduling, and reframing pain.
    Benefits: More stable function at home/work.

  3. Mindfulness and diaphragmatic breathing.
    Purpose: Ease muscle guarding and stress-linked flares.
    Mechanism: Activates parasympathetic tone, lowers sympathetic overdrive that can heighten pain.
    Benefits: Smoother effort, better sleep.

  4. Biofeedback (heart-rate or EMG).
    Purpose: Learn your safe zones.
    Mechanism: Real-time physiologic signals guide pacing/intensity.
    Benefits: Fewer overexertion episodes.

  5. Fatigue management education (“energy envelope”).
    Purpose: Match demand to capacity.
    Mechanism: Plan high- and low-demand tasks, cluster errands, pre-position supplies.
    Benefits: More good hours, fewer crash days.

  6. Workplace/school accommodations.
    Purpose: Keep participation without flares.
    Mechanism: Flexible schedules, rest breaks, task rotation, lift aids.
    Benefits: Better attendance and quality of life.

  7. Symptom/trigger diary & wearable tracking.
    Purpose: Spot personal patterns.
    Mechanism: Links sleep, stress, diet, heat, and effort to symptoms.
    Benefits: Customizes your plan effectively.

  8. Family/caregiver education.
    Purpose: Create supportive environment.
    Mechanism: Shared understanding reduces pressure to “push through” on bad days.
    Benefits: Less conflict, better outcomes.

  9. Smoking/alcohol reduction coaching.
    Purpose: Remove recovery barriers.
    Mechanism: Improves sleep quality, hydration, and muscle repair biology.
    Benefits: Fewer cramps, steadier energy.

  10. About “gene therapy.”
    Purpose: Clarify expectations.
    Mechanism: As of now, no approved gene therapy exists for AMPD1 deficiency; research is conceptual.
    Benefits: Focuses effort on proven strategies now, while staying informed about trials. accessanesthesiology.mhmedical.com

Drug treatments

Important: Medication choices must be individualized by a clinician who knows your history, labs, and risks. AMPD1 deficiency has no specific approved drug; treatments below are commonly used to manage pain, cramps, sleep, or complications.

  1. Acetaminophen (paracetamol). Class: analgesic. Dose/time: typical adult 500–1,000 mg up to every 6–8 h (max per local guidelines). Purpose: pain relief. Mechanism: central COX modulation. Side effects: liver risk at high doses/alcohol.

  2. Topical diclofenac gel. Class: NSAID (topical). Use: applied to sore areas up to 4×/day. Purpose: local anti-inflammatory analgesia with lower systemic risk. Side effects: skin irritation.

  3. Ibuprofen (oral). Class: NSAID. Use: short courses for flares. Mechanism: COX inhibition. Side effects: stomach upset, kidney risk—avoid if dehydrated; doctor guidance essential.

  4. Naproxen. Similar rationale to ibuprofen; sometimes preferred for longer effect. GI/renal cautions apply.

  5. Cyclobenzaprine (short-term). Class: muscle relaxant. Purpose: ease acute spasm at night. Side effects: drowsiness, dry mouth; short-term only.

  6. Tizanidine (selected cases). Class: α2-agonist antispasmodic. Purpose: nocturnal spasm; Side effects: sedation, low BP—medical supervision.

  7. Amitriptyline (low dose). Class: tricyclic. Purpose: chronic myalgia with sleep disturbance. Mechanism: descending pain inhibition. Side effects: anticholinergic; start low.

  8. Duloxetine. Class: SNRI. Purpose: chronic musculoskeletal pain in some patients. Side effects: nausea, sleep changes.

  9. Lidocaine 5% patch. Class: local anesthetic. Purpose: focal myofascial pain. Side effects: local rash.

  10. Ondansetron (as needed). Class: antiemetic. Purpose: nausea during severe flares/rehydration. Side effects: constipation, QT risk.

  11. Oral rehydration solution (ORS). Purpose: treat cramp-prone dehydration; not exactly a “drug,” but often prescribed pattern.

  12. IV isotonic fluids (clinical setting). Purpose: treat rhabdomyolysis risk after extreme exertion; Side effects: fluid overload if not monitored.

  13. Sodium bicarbonate (selected rhabdo with acidosis). Purpose: urine alkalinization per hospital protocol. Side effects: electrolyte shifts. (Hospital-only.)

  14. Vitamin D replacement (if deficient). Class: hormone/vitamin. Purpose: improve myalgia/strength in deficiency. Side effects: hypercalcemia if overdosed.

  15. Levothyroxine (if hypothyroid). Purpose: corrects secondary contributor to fatigue/myalgia. Side effects: dose-dependent; titrate by labs.

Dietary molecular supplement

  1. D-Ribose. Dose: commonly 2–5 g before/during activity; some case reports used higher split doses. Function/mechanism: provides a substrate for purine salvage, potentially supporting ATP pools in AMPD1 deficiency. Evidence: case reports show benefit; controlled evidence is limited/variable. PubMedSpringerLinkPMC

  2. Creatine monohydrate. Dose: 3–5 g/day. Function: boosts phosphocreatine buffer, helping rapid ATP recycling. Mechanism: donates phosphate to ADP during high demand.

  3. L-Carnitine. Dose: 1–3 g/day (split). Function: fatty-acid transport into mitochondria; may aid endurance in some myopathies.

  4. Coenzyme Q10 (ubiquinone). Dose: 100–300 mg/day. Function: electron transport chain cofactor; supports mitochondrial ATP production.

  5. Magnesium (glycinate/citrate). Dose: 200–400 mg elemental/day. Function: cofactor for ATP-dependent enzymes; can help cramps if low.

  6. Vitamin D3. Dose: individualized (often 1,000–2,000 IU/day maintenance after repletion). Function: muscle function and pain modulation when deficient.

  7. B-complex (B1, B2, B6, B12). Dose: balanced B-complex (e.g., B1 50–100 mg; B2 20–50 mg, etc.). Function: coenzymes in carbohydrate metabolism and nerve health.

  8. Taurine. Dose: 1–3 g/day. Function: membrane stabilization; may reduce cramps in some people.

  9. Omega-3 (EPA+DHA). Dose: 1–3 g/day combined EPA+DHA. Function: anti-inflammatory effects; may reduce muscle soreness.

  10. Beta-alanine. Dose: 2–4 g/day in divided doses. Function: raises carnosine to buffer acidity in fast-twitch fibers; may help high-intensity tolerance.

Evidence quality varies; avoid stacking many supplements at once and monitor for interactions.

Immunity-booster / regenerative / stem-cell” drugs—

There are no approved immune-booster, regenerative, or stem-cell drugs for AMPD1 deficiency. Using such therapies outside clinical trials is not recommended. Here’s a safe-practice summary:

  1. Gene therapy for AMPD1: Status: investigational concept; not available clinically.

  2. Stem-cell infusions (any type): Status: no evidence for AMPD1; potential risks; avoid outside trials.

  3. Experimental myostatin inhibitors: Status: not approved here; unknown benefit–risk.

  4. Growth hormone/anabolic agents: Status: not indicated; significant risks.

  5. High-dose immune modulators: Status: no role in AMPD1.

  6. What to do instead: vaccinations, sleep, nutrition, graded training, and address deficiencies—these are the safe “immune supports.” accessanesthesiology.mhmedical.com

Surgeries

There is no surgery that treats AMPD1 deficiency itself. Procedures are only for complications or diagnosis:

  1. Muscle biopsy (diagnostic) when genetics are inconclusive—tiny sample to measure enzyme staining. PubMed

  2. Fasciotomy (rare) if acute compartment syndrome develops after extreme exertion (emergency).

  3. Intravenous line placement for aggressive fluids in rhabdomyolysis.

  4. Temporary dialysis for severe kidney injury from rhabdomyolysis (rare).

  5. Central venous access (hospital setting) if prolonged management is needed.

Preventions

  1. Build fitness slowly; avoid sudden “hero” workouts.

  2. Warm-up and cool-down every session.

  3. Hydrate and replace electrolytes—especially in heat.

  4. Pre-fuel with easily digested carbohydrate when activity will be longer or harder.

  5. Schedule rest days and high/low days.

  6. Don’t exercise with fever or flu-like illness.

  7. Avoid fasting and extreme low-carb or crash diets.

  8. Review myotoxic medications with your clinician; monitor if you need a statin.

  9. Correct thyroid or vitamin D issues.

  10. Keep vaccinations up to date to reduce illness-related setbacks.

When to see doctors

  • Dark urine, severe muscle swelling, or severe pain after exertion (possible rhabdomyolysis).

  • New, persistent weakness or rapidly worsening tolerance.

  • Recurrent flares despite careful pacing and fueling.

  • Considering new medicines that can affect muscles (e.g., a statin) or major training changes.

  • Heat illness symptoms during workouts.

  • Planning pregnancy or seeking genetic counseling for family risk. Rare Diseases Info

What to eat and what to avoid

  1. Eat regularly; avoid long fasting.

  2. Pre-exercise fuel: a small carbohydrate snack 30–60 minutes before longer or harder sessions.

  3. During prolonged efforts: sip fluids; consider electrolyte drinks.

  4. Post-exercise: mix carbs with protein for recovery (e.g., yogurt + fruit).

  5. Prefer whole grains, fruits, legumes, and lean proteins to stabilize energy.

  6. Get healthy fats (olive oil, nuts, fish) for recovery.

  7. Avoid crash diets or extreme ketogenic plans unless supervised—low carbohydrate can worsen tolerance.

  8. Limit alcohol (dehydration) and excess caffeine before heat or intense sessions.

  9. Ensure magnesium and vitamin D adequacy (food + guided supplementation).

  10. Trial D-ribose or other supplements only with clinician oversight (evidence mixed). PubMedSpringerLink

FAQs

  1. Is AMPD1 deficiency dangerous? Most people are safe; some have exercise intolerance. Rarely, severe exertion can cause rhabdomyolysis—know warning signs. Rare Diseases Info

  2. Will I lose muscle? Not typically. Smart training improves function.

  3. Can I play sports? Yes—with pacing, hydration, fueling, and gradual build-up.

  4. Why do I tire faster? The enzyme that helps recycle energy in hard efforts is low, so energy backup is limited. MedlinePlus

  5. Is it the same as mitochondrial disease? No. It’s a purine recycling problem, though both affect exercise tolerance.

  6. Do I need a biopsy? Often, genetic testing confirms the diagnosis; biopsy is reserved for unclear cases. MedlinePlusPubMed

  7. Will D-ribose help me? Some case reports suggest benefit; evidence is mixed. A careful, clinician-supervised trial may be reasonable. PubMedSpringerLinkPMC

  8. What about creatine? Can help short-burst energy buffering for some; trial with guidance.

  9. Are there approved medicines to fix the enzyme? No. Treatment is supportive. accessanesthesiology.mhmedical.com

  10. Can I donate blood or organs? Usually yes; ask your doctor.

  11. Will my kids have it? Risk depends on partner’s carrier status; consider genetic counseling. MedlinePlus

  12. Can it be silent? Yes; many people with AMPD1 variants have no symptoms. Rare Diseases Info

  13. Why does heat make it worse? Heat raises overall stress, fluid loss, and muscle energy demand.

  14. How do I prevent cramps? Hydration, electrolytes, steady build-up, gentle stretching, and adequate magnesium if low.

  15. Who should be on my care team? Primary care, sports/neuromuscular clinician, physiotherapist, dietitian, and (when needed) genetics.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 08, 2025.

  1. Rare Diseases and Medical Genetics.[rxharun.com]
  2. i2023_IFPMA_Rare_Diseases_Brochure_28Feb2017_FINAL.[rxharun.com]
  3. the-UK-rare-diseases-framework.[rxharun.com]
  4. National-Recommendations-for-Rare-Disease-Health-Care-Summary.[rxharun.com]
  5. History of rare diseases and their genetic.[rxharun.com]
  6. health-care-and-rare-disorders.[rxharun.com]
  7. Rare Disease Registries.[rxharun.com]
  8. autoimmune-Rare-Genetic-Diseases.[rxharun.com]
  9. Rare Genetic Diseases.[rxharun.com]
  10. rare-disease-day.[rxharun.com]
  11. Rare_Disease_Drugs_e.[rxharun.com]
  12. fda-CDER-Rare-Diseases-Public-Workshop-Master.[rxharun.com]
  13. rare-and-inherited-disease-eligibility-criteria.[rxharun.com]
  14. FDA-rare-disease-list.pdf-rxharun.com1 Human-Gene-Therapy-for-Rare Diseases_Jan_2020fda.[rxharun.com]
  15. FDA-rare-disease-lists.[rxharun.com]
  16. 30212783fnl_Rare Disease.[rxharun.com]
  17. FDA-rare-disease-list.[rxharun.com]
  18. List of rare disease.[rxharun.com]
  19. Genome Res.-2025-Steyaert-755-68.[rxharun.com]
  20. uk-practice-guidelines-for-variant-classification-v4-01-2020.[rxharun.com]
  21. PIIS2949774424010355.[rxharun.com]
  22. hidden-costs-2016.[rxharun.com]
  23. B156_CONF2-en.[rxharun.com]
  24. IRDiRC_State-of-Play-2018_Final.[rxharun.com]
  25. IRDR_2022Vol11No3_pp96_160.[rxharun.com]
  26. from-orphan-to-opportunity-mastering-rare-disease-launch-excellence.[rxharun.com]
  27. Rare disease fda.[rxharun.com]
  28. England-Rare-Diseases-Action-Plan-2022.[rxharun.com]
  29. SCRDAC 2024 Report.[rxharun.com]
  30. CORD-Rare-Disease-Survey_Full-Report_Feb-2870-2.[rxharun.com]
  31. Stats-behind-the-stories-Genetic-Alliance-UK-2024.[rxharun.com]
  32. rare-and-inherited-disease-eligibility-criteria-v2.[rxharun.com]
  33. ENG_White paper_A4_Digital_FINAL.[rxharun.com]
  34. UK_Strategy_for_Rare_Diseases.[rxharun.com]
  35. MalaysiaRareDiseaseList.[rxharun.com]
  36. EURORDISCARE_FULLBOOKr.[rxharun.com]
  37. EMHJ_1999_5_6_1104_1113.[rxharun.com]
  38. national-genomic-test-directory-rare-and-inherited-disease-eligibilitycriteria-.[rxharun.com]
  39. be-counted-052722-WEB.[rxharun.com]
  40. RDI-Resource-Map-AMR_MARCH-2024.[rxharun.com]
  41. genomic-analysis-of-rare-disease-brochure.[rxharun.com]
  42. List-of-rare-diseases.[rxharun.com]
  43. RDI-Resource-Map-AFROEMRO_APRIL[rxharun.com]
  44. rdnumbers.[rxharun.com] .
  45. Rare disease atoz .[rxharun.com]
  46. EmanPublisher_12_5830biosciences-.[rxharun.com]

  1. https://www.ncbi.nlm.nih.gov/books/NBK208609/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6279436/
  3. https://rarediseases.org/rare-diseases/
  4. https://rarediseases.info.nih.gov/diseases
  5. https://en.wikipedia.org/w/index.php?title=Category:Rare_diseases
  6. https://en.wikipedia.org/wiki/List_of_genetic_disorders
  7. https://en.wikipedia.org/wiki/Category:Genetic_diseases_and_disorders
  8. https://medlineplus.gov/genetics/condition/
  9. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  10. https://www.fda.gov/patients/rare-diseases-fda
  11. https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/support-clinical-trials-advancing-rare-disease-therapeutics-start-pilot-program
  12. https://accp1.onlinelibrary.wiley.com/doi/full/10.1002/jcph.2134
  13. https://www.mayoclinicproceedings.org/article/S0025-6196%2823%2900116-7/fulltext
  14. https://www.ncbi.nlm.nih.gov/mesh?
  15. https://www.rarediseasesinternational.org/working-with-the-who/
  16. https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03322-7
  17. https://www.rarediseasesnetwork.org/
  18. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/rare-disease
  19. https://www.raregenomics.org/rare-disease-list
  20. https://www.astrazeneca.com/our-therapy-areas/rare-disease.html
  21. https://bioresource.nihr.ac.uk/rare
  22. https://www.roche.com/solutions/focus-areas/neuroscience/rare-diseases
  23. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  24. https://www.genomicsengland.co.uk/genomic-medicine/understanding-genomics/rare-disease-genomics
  25. https://www.oxfordhealth.nhs.uk/cit/resources/genetic-rare-disorders/
  26. https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01026
  27. https://wikicure.fandom.com/wiki/Rare_Diseases
  28. https://www.wikidoc.org/index.php/List_of_genetic_disorders
  29. https://www.medschool.umaryland.edu/btbank/investigators/list-of-disorders/
  30. https://www.orpha.net/en/disease/list
  31. https://www.genetics.edu.au/SitePages/A-Z-genetic-conditions.aspx
  32. https://ojrd.biomedcentral.com/
  33. https://health.ec.europa.eu/rare-diseases-and-european-reference-networks/rare-diseases_en
  34. https://bioportal.bioontology.org/ontologies/ORDO
  35. https://www.orpha.net/en/disease/list
  36. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions
  37. https://www.gao.gov/products/gao-25-106774
  38. https://www.gene.com/partners/what-we-are-looking-for/rare-diseases
  39. https://www.genome.gov/For-Patients-and-Families/Genetic-Disorders
  40. https://geneticalliance.org.uk/support-and-information/a-z-of-genetic-and-rare-conditions/
  41. https://my.clevelandclinic.org/health/diseases/21751-genetic-disorders
  42. https://globalgenes.org/rare-disease-facts/
  43. https://www.nidcd.nih.gov/directory/national-organization-rare-disorders-nord
  44. https://byjus.com/biology/genetic-disorders/
  45. https://www.cdc.gov/genomics-and-health/about/genetic-disorders.html
  46. https://www.genomicseducation.hee.nhs.uk/doc-type/genetic-conditions/
  47. https://www.thegenehome.com/basics-of-genetics/disease-examples
  48. https://www.oxfordhealth.nhs.uk/cit/resources/genetic-rare-disorders/
  49. https://www.pfizerclinicaltrials.com/our-research/rare-diseases
  50. https://clinicaltrials.gov/ct2/results?recrs
  51. https://apps.who.int/gb/ebwha/pdf_files/EB116/B116_3-en.pdf
  52. https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.21-0239
  53. https://www.nibib.nih.gov/
  54. https://www.nei.nih.gov/
  55. https://oxfordtreatment.com/
  56. https://www.nidcd.nih.gov/health/https://consumer.ftc.gov/articles/
  57. https://www.nccih.nih.gov/health
  58. https://catalog.ninds.nih.gov/
  59. https://www.aarda.org/diseaselist/
  60. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets
  61. https://www.nibib.nih.gov/
  62. https://www.nia.nih.gov/health/topics
  63. https://www.nichd.nih.gov/
  64. https://www.nimh.nih.gov/health/topics
  65. https://www.nichd.nih.gov/
  66. https://www.niehs.nih.gov/
  67. https://www.nimhd.nih.gov/
  68. https://www.nhlbi.nih.gov/health-topics
  69. https://obssr.od.nih.gov/.
  70. https://www.nichd.nih.gov/health/topics
  71. https://rarediseases.info.nih.gov/diseases
  72. https://beta.rarediseases.info.nih.gov/diseases
  73. https://orwh.od.nih.gov/

RX Medical Knowledge Graph

Explore this medical topic

Continue through verified related conditions, investigations, medicines, and patient guides. These links are educational and do not replace professional medical advice.

Related medical topics

Congenital Enterocyte Heparan Sulfate Deficiency73% relationship confidence Dol-P-Mannosyltransferase Deficiency73% relationship confidence Dolichol-Phosphate-Mannose Synthase 1 Deficiency73% relationship confidence Basel-Vanagaite-Smirin-Yosef Syndrome68% relationship confidence Bathing Suit Ichthyosis (BSI)68% relationship confidence Charcot-Marie-Tooth Neuropathy With Focal Segmental Glomerulonephritis68% relationship confidence Congenital Cataract-Ichthyosis Syndrome68% relationship confidence Congenital Cataract-Microcephaly-Nevus Flammeus Simplex-Severe Intellectual Disability Syndrome68% relationship confidence
RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Myoadenylate Deaminase Deficiency (MADD)

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Is this article a replacement for a doctor?

No. It is educational content only. Patients should consult a qualified clinician for diagnosis and treatment.

When should I seek urgent care?

Seek urgent care for severe symptoms, rapidly worsening condition, breathing difficulty, severe pain, neurological changes, or any emergency warning sign.

A global war against illness

Help this medical guide reach someone who may need it

Share reliable health information with a patient, family member, caregiver, or colleague. Reading and awareness can help people ask better questions and seek appropriate care.

Continue exploring

Explore this topic across the RX Medical Library

Open a focused A–Z pathway or continue with closely related indexed articles. These links are educational and do not replace personal medical care.

Search this topic
Diseases A–Z Drugs A–Z Lab Tests A–Z Cancer A–Z
More from this topic
  1. Congenital Enterocyte Heparan Sulfate Deficiency

    DefinitionCongenital? enterocyte heparan sulfate deficiency is a very rare, severe, genetic intestinal disease. In this condition, the small bowel lining cells, called enterocytes, do not show...

    April 3, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  2. Congenital ectropion uveae

    DefinitionCongenital? ectropion uveae, often shortened to CEU, is a very rare eye condition present from birth. In this condition, the dark pigment layer that normally stays...

    April 2, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  3. Congenital Dyserythropoietic Anemia, Type III

    DefinitionCongenital? dyserythropoietic anemia?, type III, also called CDA type III, is a very rare inherited blood disease. In this disease, the bone marrow tries to make...

    April 2, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  4. Congenital Dyserythropoietic Anemia Type I

    DefinitionCongenital? dyserythropoietic anemia?, type I, usually called CDA type I, is a rare inherited blood disease. In this disease, the bone marrow tries to make red...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  5. Congenital Dyserythropoietic Anemia Due to KLF1 Mutation

    DefinitionCongenital? dyserythropoietic anemia? due to KLF1 mutation is a very rare inherited red blood cell disease. In most reported cases, doctors describe it as congenital? dyserythropoietic...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  6. Congenital Dyserythropoietic Anemia Due to KLF1 Mutation

    DefinitionCongenital? dyserythropoietic anemia? due to KLF1 mutation is a very rare inherited red blood cell disease. In most reported cases, doctors describe it as congenital? dyserythropoietic...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  7. HEMPAS – Hereditary Erythroblast Multinuclearity with Positive Acid Serum Test

    DefinitionHEMPAS – Hereditary Erythroblast Multinuclearity with Positive Acid Serum Test is a rare inherited blood disease. Its full old name is hereditary erythroblastic multinuclearity with positive...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  8. Congenital Dyserythropoietic Anemia Type 2

    DefinitionCongenital? dyserythropoietic anemia? type 2, also called CDA type II, is a rare inherited blood disease. In this disease, the body makes red blood cells in...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  9. Component of Oligomeric Golgi Complex 2–Congenital Disorder of Glycosylation

    DefinitionComponent of oligomeric Golgi complex 2–congenital? disorder of glycosylation is usually called COG2-CDG. It is a very rare inherited metabolic disease. In this disease, both copies...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)
  10. Congenital Disorder of Glycosylation, Type IIq

    DefinitionCongenital? disorder of glycosylation, type IIq, is a very rare inherited metabolic disease. It is now also commonly called COG2-CDG because it is caused by harmful...

    April 1, 2026 • Rx Autoimmune, Genetic and Rare Diseases (A - Z)